{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:57:44Z","timestamp":1793159864709,"version":"4.5.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>With the emergence of disease-modifying therapies for Alzheimer\u2019s disease (AD), there is an urgent need for scalable, accurate, and well-validated blood test alternatives to positron emission topography (PET) and lumbar punctures for identifying amyloid pathology to facilitate identification of candidates for therapy. Plasma p-Tau 217 has emerged as a plasma-based biomarker with sufficient sensitivity and specificity to both rule out and rule in amyloid pathology with high confidence, potentially serving as a readily scalable non-invasive test to aid AD diagnosis. In this report, we describe robust analytical and clinical validation of a lab developed test for plasma p-Tau 217 suitable for clinical diagnostic use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A high sensitivity digital immunoassay using single molecule array (Simoa) technology was developed for plasma p-Tau 217 utilizing a 2-cutoff approach. The assay was analytically validated with industry standard protocols and clinically validated across 873 symptomatic individuals from two independent clinical cohorts using PET or cerebrospinal fluid (CSF) biomarkers as comparators.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The assay exhibited acceptable analytical characteristics with an analytical sensitivity enabling measurement of plasma p-Tau 217 in all clinical samples. Excluding results between the two cutoffs, clinical sensitivity, specificity, and agreement with comparator methods (accuracy) were &amp;gt;90%, with 30.9% of the samples falling in the intermediate zone between the two cutoffs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The performance characteristics of the Simoa p-Tau 217 assay align with current accuracy recommendations for blood-based biomarker test performance for diagnostic use, making the test suitable for clinical use under the Clinical Laboratory Improvement Act (CLIA) as a diagnostic plasma test to aid in Alzheimer\u2019s diagnosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2025.1568971","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T08:00:02Z","timestamp":1752134402000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Analytical and clinical validation of a high accuracy fully automated digital immunoassay for plasma phospho-Tau 217 for clinical use in detecting amyloid pathology"],"prefix":"10.3389","volume":"16","author":[{"given":"David","family":"Wilson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenakshi","family":"Khare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gallen","family":"Triana-Baltzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Wolfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Sheehy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Copeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyndal","family":"Hesterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Jeanette","family":"Vasko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiesje M.","family":"van der Flier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge M. W.","family":"Verberk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte E.","family":"Teunissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/alz.12724","article-title":"Plasma A\u03b242\/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: a cross-sectional and longitudinal study in the AIBL cohort","volume":"19","author":"Chatterjee","year":"2023","journal-title":"Alzheimers Dement"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e12204","DOI":"10.1002\/dad2.12204","article-title":"Development and validation of a high-sensitivity assay for measuring p217+tau in plasma","volume":"13","author":"Triana-Baltzer","year":"2021","journal-title":"Alzheimers Dement (Amst)"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e12307","DOI":"10.1002\/dad2.12307","article-title":"Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum","volume":"14","author":"Dore","year":"2022","journal-title":"Alzheimers Dement (Amst)"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"828","DOI":"10.14283\/jpad.2023.83","article-title":"Two-year prognostic utility of plasma p217+tau across the Alzheimer's continuum","volume":"10","author":"Feizpour","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimers Dement"},{"key":"ref6","year":""},{"key":"ref7","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41582-024-00977-5","article-title":"Acceptable performance of blood biomarker tests of amyloid pathology - recommendations from the global CEO initiative on Alzheimer's disease","volume":"20","author":"Schindler","year":"2024","journal-title":"Nat Rev Neurol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1177\/2211068215589580","article-title":"The Simoa HD-1 analyzer: a novel fully automated digital immunoassay analyzer with single-molecule sensitivity and multiplexing","volume":"21","author":"Wilson","year":"2016","journal-title":"J Lab Autom"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nbt.1641","article-title":"Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations","volume":"28","author":"Rissin","year":"2010","journal-title":"Nat Biotechnol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1039\/c2lc20744c","article-title":"Isolation and detection of single molecules on paramagnetic beads using sequential fluid flows in microfabricated polymer array assemblies","volume":"12","author":"Kan","year":"2012","journal-title":"Lab Chip"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.3233\/JAD-200544","article-title":"Discovery and functional characterization of hPT3, a humanized anti-phospho tau selective monoclonal antibody","volume":"77","author":"Van Kolen","year":"2020","journal-title":"J Alzheimers Dis"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.3233\/JAD-200463","article-title":"Development and validation of a high sensitivity assay for measuring p217\u200a+\u200atau in cerebrospinal fluid","volume":"77","author":"Triana-Baltzer","year":"2020","journal-title":"J Alzheimers Dis"},{"key":"ref13","volume-title":"Evaluation of the linearity of quantitative measurement procedures","year":"2020"},{"key":"ref14","volume-title":"Evaluation of detection capability for clinical laboratory measurement procedures","year":"2012"},{"key":"ref15","volume-title":"Evaluation of precision of quantitative measurement procedures","year":"2014"},{"key":"ref16","volume-title":"Interference testing in clinical chemistry, approved guideline","year":"2018"},{"key":"ref17","volume-title":"Evaluation of stability of in vitro medical laboratory test reagents","year":"2023"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3233\/JAD-132306","article-title":"Optimizing patient care and research: the Amsterdam dementia cohort","volume":"41","author":"van der Flier","year":"2014","journal-title":"J Alzheimers Dis"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.3233\/JAD-170850","article-title":"Amsterdam dementia cohort: performing research to optimize care","volume":"62","author":"van der Flier","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.1002\/alz.13722","article-title":"The Bio-Hermes study: biomarker database developed to investigate blood-based and digital biomarkers in community-based, diverse populations clinically screened for Alzheimer's disease","volume":"20","author":"Mohs","year":"202","journal-title":"Alzheimers Dement"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/wnl.34.7.939","article-title":"Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1001\/archneur.56.3.303","article-title":"Mild cognitive impairment: clinical characterization and outcome","volume":"56","author":"Petersen","year":"1999","journal-title":"Arch Neurol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"e12182","DOI":"10.1002\/dad2.12182","article-title":"Comparing CSF amyloid-beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status","volume":"13","author":"Willemse","year":"2021","journal-title":"Alzheimers Dement (Amst)"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"6115","DOI":"10.1002\/alz.14088","article-title":"Development of thresholds and a visualization tool for use of a blood test in routine clinical dementia practice","volume":"20","author":"Verberk","year":"2024","journal-title":"Alzheimers Dement"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/s43587-023-00471-5","article-title":"A two-step workflow based on plasma p-tau217 to screen for amyloid \u0152\u2264 positivity with further confirmatory testing only in uncertain cases","volume":"3","author":"Brum","year":"2023","journal-title":"Nat Aging"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jamaneurol.2023.4596","article-title":"Plasma biomarker strategy for selecting patients with Alzheimer disease for antiamyloid immunotherapies","volume":"81","author":"Mattsson-Carlgren","year":"2024","journal-title":"JAMA Neurol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"4967","DOI":"10.1002\/alz.13026","article-title":"Equivalence of plasma p-tau217 with cerebrospinal fluid in the diagnosis of Alzheimer's disease","volume":"19","author":"Therriault","year":"2023","journal-title":"Alzheimers Dement"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/alz.12841","article-title":"Plasma and CSF biomarkers in a memory clinic: head-to-head comparison of phosphorylated tau immunoassays","volume":"19","author":"Ashton","year":"2023","journal-title":"Alzheimers Dement"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","article-title":"Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology","volume":"81","author":"Ashton","year":"2024","journal-title":"JAMA Neurol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jalz.2018.09.001","article-title":"Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology","volume":"15","author":"La Joie","year":"2019","journal-title":"Alzheimers Dement"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.jalz.2015.02.004","article-title":"Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study","volume":"11","author":"Sabri","year":"2015","journal-title":"Alzheimers Dement"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1001\/jamaneurol.2022.4485","article-title":"Association of Phosphorylated tau Biomarkers with amyloid positron emission tomography vs tau positron emission tomography","volume":"80","author":"Therriault","year":"2023","journal-title":"JAMA Neurol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"4463","DOI":"10.1002\/alz.13393","article-title":"Plasma p-tau231 and p-tau217 inform on tau tangles aggregation in cognitively impaired individuals","volume":"19","author":"Ferreira","year":"2023","journal-title":"Alzheimers Dement"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"105046","DOI":"10.1016\/j.ebiom.2024.105046","article-title":"Comparison of two plasma p-tau217 assays to detect and monitor Alzheimer's pathology","volume":"102","author":"Therriault","year":"2024","journal-title":"EBioMedicine"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1101\/2025.03.31.25324984","article-title":"Clinical performance of scalable automated p-tau 217 multi-analyte algorithmic blood test with reduced intermediate zone using multiplexed digital immunoassay","author":"Wilson","year":"2025","journal-title":"medRxiv"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13195-022-01005-8","article-title":"Diagnostic and prognostic performance to detect Alzheimer's disease and clinical progression of a novel assay for plasma p-tau217","volume":"14","author":"Groot","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1002\/alz.13764","article-title":"Clinical validation of the PrecivityAD2 blood test: a mass spectrometry-based test with algorithm combining %p-tau217 and A\u03b242\/40 ratio to identify presence of brain amyloid","volume":"20","author":"Meyer","year":"2024","journal-title":"Alzheimers Dement"},{"key":"ref39","article-title":"A two-step workflow based on plasma p-tau217 to screen for a\u03b2: the impact of chronic kidney disease","author":"Ashton","year":"2024"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1568971\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T08:00:04Z","timestamp":1752134404000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1568971\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,9]]},"references-count":39,"alternative-id":["10.3389\/fneur.2025.1568971"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1568971","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.10.31.24316186","asserted-by":"object"}]},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,9]]},"article-number":"1568971"}}